ReviewTherapeutic advances in psychopharmacology2019
Are we getting any better at staying better? The long view on relapse and recovery in first episode nonaffective psychosis and schizophrenia.
Review in Therapeutic advances in psychopharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 45 citations in OpenAlex.
- Childhood premorbid adjustment as a marker for 20-year impairments in schizophrenia spectrum disorder: results from the OPUS study.European child & adolescent psychiatry · 2026Trial
- Clinical Utility of Cariprazine in the Management of Acute Schizophrenia: Current Evidence and Practical Recommendations.Actas espanolas de psiquiatria · 2026Review
- Validation and reliability of the Thai version of the glasgow antipsychotic side-effect scale (GASS) in patients with schizophrenia.Frontiers in pharmacology · 2026Article
- Lay health worker-delivered case management for early episodes of psychosis in Bangkok, Thailand (Lay-CARE): a single-centre, pragmatic, randomised controlled trial.The Lancet regional health. Southeast Asia · 2025Article
- Should we consider microbiota-based interventions as a novel therapeutic strategy for schizophrenia? A systematic review and meta-analysis.Brain, behavior, & immunity - health · 2025Article
- Knowing is Half the Battle: The Factors Leading to Efficient Recruitment of Representative Samples in Schizophrenia Research.Pharmaceutical medicine · 2025Article
- Does Slow and Steady Win the Race? Rates of Antipsychotic Discontinuation, Antipsychotic Dose, and Risk of Psychotic Relapse.Schizophrenia bulletin · 2024Article
- Psychosocial and psychological interventions for schizophrenia relapse prevention: A bibliometric analysis.Global mental health (Cambridge, England) · 2024Article
- Life engagement in people living with schizophrenia: predictors and correlates of patient life engagement in a large sample of people living in the community.Psychological medicine · 2023Article
- A Systematic Review on the Effectiveness of Antipsychotic Drugs on the Quality of Life of Patients with Schizophrenia.Brain sciences · 2023Review
- New Developments in the Treatment of Schizophrenia: An Expert Roundtable.The international journal of neuropsychopharmacology · 2023Article
- The relationship between area levels of involuntary psychiatric care and patient outcomes: a longitudinal national register study from Norway.BMC psychiatry · 2023Article
- Challenges and Strategies for the Recruitment of Patients With Schizophrenia in a Research Setting.The international journal of neuropsychopharmacology · 2022Article
- Affective Dysregulation Precedes Emergence of Psychosis-Like Experiences in a Community Sample of Young Adults.Schizophrenia bulletin · 2022Article
- Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation.Therapeutic advances in psychopharmacology · 2022Article
- Results from PSIPROSPER: A multicenter retrospective study to analyze the impact of treatment with paliperidone palmitate 1-month on clinical outcomes and hospital resource utilization in adult patients with schizophrenia in Portugal.Frontiers in psychiatry · 2022Article
- Trace Amine-Associated Receptor 1 as a Target for the Development of New Antipsychotics: Current Status of Research and Future Directions.CNS drugs · 2021Review
- Early intervention in psychosis during the COVID-19 pandemic: Maudsley recommendations.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2021Article
- Precision clinical trials: a framework for getting to precision medicine for neurobehavioural disorders.Journal of psychiatry & neuroscience : JPN · 2021Review
- Associations Between Relapses and Psychosocial Outcomes in Patients With Schizophrenia in Real-World Settings in the United States.Frontiers in psychiatry · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Relapse in, and recovery from, schizophrenia has been acknowledged since the disease was first described. In this review the authors summarize the long-term (>100 years) data on relapse and recovery in schizophrenia by reviewing the extant older and modern relevant literature. The authors systematically question the utility of pharmacological and nonpharmacological interventions, with an emphasis on first episode nonaffective psychosis. The method used is a narrative review of earlier meta-analytic and systematic reviews. Antipsychotic medication discontinuation studies suggest a role for prophylactic maintenance treatment in the majority of people with schizophrenia, despite recent debate on this subject. The authors conclude that long-term outcomes, including relapse and recovery rates, have improved in the last 100 years, though prospectively identifying those people who do not require long-term antipsychotic treatment has not yet been possible. Data also suggests that interventions and outcomes during the first 5 years of the disease can influence the long-term schizophrenia trajectory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.